Table 2 Effect of prescription doses of phosphate binders and ESA after 5 months of observation
Mean | SD | SE | ANOVA | 95% CI | Minimum | Maximum | |||
|---|---|---|---|---|---|---|---|---|---|
Lower limit | Upper limit | ||||||||
Total amount of prescription dose (per 5 months) | FC | 142.9 | 80.2 | 8.0 | * | 127.0 | 158.7 | 10.5 | 437.8 |
SF | 132.1 | 84.0 | 9.3 | * | 113.6 | 150.5 | 5.3 | 399.0 | |
LC | 208.7 | 89.9 | 8.0 | * | 192.8 | 224.5 | 35.0 | 462.0 | |
Total | 166.8 | 91.9 | 5.2 | 156.5 | 177.1 | 5.3 | 462.0 | ||
Total prescription dose/starting dose | FC | 0.6 | 0.4 | 0.0 | * | 0.6 | 0.7 | 0.0 | 2.0 |
SF | 1.1 | 0.7 | 0.1 | * | 1.0 | 1.3 | 0.0 | 3.4 | |
LC | 1.8 | 0.8 | 0.1 | * | 1.7 | 1.9 | 0.3 | 4.0 | |
Total | 1.2 | 0.8 | 0.0 | 1.2 | 1.3 | 0.0 | 4.0 | ||
Phosphate change rate (%) [(Pi_end − Pi_week_0) × 100/Pi_week_0] | FC | 2.9 | 31.5 | 3.1 | −3.4 | 9.1 | −45.1 | 116.3 | |
SF | −10.8 | 22.6 | 2.5 | * | −15.8 | −5.9 | −54.0 | 48.8 | |
LC | −3.2 | 27.8 | 2.5 | −8.1 | 1.7 | −59.5 | 152.4 | ||
Total | −3.3 | 28.3 | 1.6 | −6.4 | −0.1 | −59.5 | 152.4 | ||
Number of times ferritin ≥300 ng/mL | FC | 0.1 | 0.4 | 0.0 | 0.0 | 0.2 | 0.0 | 4.0 | |
SF | 2.3 | 1.5 | 0.2 | * | 1.9 | 2.6 | 0.0 | 5.0 | |
LC | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 2.0 | ||
Total | 0.6 | 1.3 | 0.1 | 0.5 | 0.8 | 0.0 | 5.0 | ||
Total amount of ESA dose (μg) # | FC | 440.0 | 567.6 | 56.5 | 327.9 | 552.0 | 0.0 | 3960.0 | |
SF | 265.7 | 339.2 | 37.5 | * | 191.2 | 340.2 | 0.0 | 1880.0 | |
LC | 424.7 | 445.4 | 39.7 | 346.2 | 503.2 | 0.0 | 2640.0 | ||
Total | 387.5 | 469.9 | 26.7 | 334.9 | 440.1 | 0.0 | 3960.0 | ||